Philip A Chambers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2838808/publications.pdf

Version: 2024-02-01

623188 887659 1,983 18 14 17 citations g-index h-index papers 18 18 18 3566 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 1261-1270.	0.8	593
2	<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. Journal of Clinical Oncology, 2009, 27, 5931-5937.	0.8	517
3	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncology, The, 2013, 14, 749-759.	5.1	333
4	<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp> , <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials. Journal of Pathology, 2016, 238, 562-570.	2.1	185
5	Intra-tumoral Heterogeneity of <i>KRAS </i> and <i>BRAF </i> Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing. Analytical Cellular Pathology, 2011, 34, 61-66.	0.7	70
6	Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype. Clinical Cancer Research, 2005, $11,5740$ -5747.	3.2	56
7	Ischemia- reperfusion Injury and Its Influence on the Epigenetic Modification of the Donor Kidney Genome. Transplantation, 2008, 86, 1818-1823.	0.5	45
8	Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Analytical Cellular Pathology, 2011, 34, 61-6.	0.7	42
9	Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. Journal of Pathology, 2009, 218, 122-130.	2.1	32
10	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. British Journal of Cancer, 2017, 117, 1286-1294.	2.9	22
11	Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis. PLoS ONE, 2015, 10, e0139698.	1.1	21
12	Integrated genomic and transcriptional analysis of the in vitro evolution of telomeraseâ€immortalized urothelial cells (TERTâ€NHUC). Genes Chromosomes and Cancer, 2009, 48, 694-710.	1.5	20
13	Clinicopathologic Features of V600E and V600K Melanomaâ€"Letter. Clinical Cancer Research, 2012, 18, 6792-6792.	3.2	14
14	Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like―Status, in Both Blood and Tumour DNA. PLoS ONE, 2016, 11, e0160174.	1.1	14
15	In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis, 2011, 32, 516-521.	1.3	10
16	Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics. Human Mutation, 2013, 34, 248-254.	1.1	8
17	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	1
18	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	0